Petrelintide

Dosing from the Literature

Published for fat loss: Phase 1 trial doses only, weekly doses stepped up every two weeks to 2.4, 4.8 or 9.0 mg over 16 weeks. Not published: the five Phase 2 dose levels; no dose is approved.

No dose of petrelintide is approved. The table records the doses given in Zealand Pharma’s trials, as the paper, the conference abstracts and the trial records publish them. They are trial doses, not recommendations. The Phase 2 dose levels have not been disclosed in any document read for this page.

What It Is

Petrelintide (development code ZP8396; Roche code RO7895515) is an analog of human amylin, the hormone that pancreatic beta cells release with insulin after a meal as a satiety signal (Fischer Munch et al., 2025). Scientists at Zealand Pharma, with Boehringer Ingelheim co-authors, described its design in 2025: the compound their paper calls peptide 40 was then named petrelintide (Fischer Munch et al., 2025). Zealand is developing it as a once-weekly injection for weight management (Brændholt Olsen et al., 2026).

The design goals were a long half-life, no fibril formation and chemical stability around neutral pH, so that it can be mixed into one formulation with other peptide drugs; the paper contrasts this with pramlintide and other amylin analogs, which have to be formulated at acidic pH (Fischer Munch et al., 2025). PubChem lists its formula as C185H305N49O61 and its molecular weight as 4,192 g/mol (PubChem, CID 172915807).

In March 2025, Roche and Zealand agreed to co-develop and co-commercialize petrelintide, alone and as a fixed-dose combination with Roche’s GLP-1/GIP receptor agonist CT-388. Zealand was to receive USD 1.65 billion upfront and up to USD 5.3 billion in total, and profits and losses are shared 50/50 in the United States and Europe (Roche, March 12, 2025). CT-388 is now named enicepatide (Zealand Pharma, April 29, 2026).

The two Phase 1 trials, run from 2021 to 2024, were published in 2026 (Brændholt Olsen et al., 2026). The Phase 2 ZUPREME-1 trial, in 493 adults without diabetes, reported topline results on March 5, 2026 and more detail at the American Diabetes Association meeting in June 2026; Zealand said the full results would be published later in 2026 (Zealand Pharma, March 5 and June 5, 2026). ZUPREME-2, in 221 adults with type 2 diabetes, was completed on August 13, 2026 with no results posted (NCT06926842). On April 29, 2026, Zealand and Roche announced the decision to take petrelintide into Phase 3, and three Roche-sponsored Phase 3 trials were first posted on ClinicalTrials.gov on September 28, 2026 (NCT07843498, NCT07843485, NCT07843472).

What has not been published: the five Phase 2 dose levels, a full paper on either Phase 2 trial, and any analysis of petrelintide sold outside the trials. PubMed returned seven records for petrelintide or ZP8396 on September 29, 2026: the chemistry paper, the Phase 1 paper, four reviews and a paper on a different amylin agonist.

Mechanism of Action

The mechanism data below come from cell assays, the Phase 1 trials and one company abstract. Receptor and brain-site statements are as the cited papers make them.

• Amylin receptor 3 (AMY3R) and calcitonin receptor (CTR) — In cAMP assays in COS7 cells, petrelintide activated AMY3R with a half-maximal concentration (EC50) of 0.33 nM, against 0.51 nM for human amylin, and CTR with an EC50 of 0.32 nM, against 3.5 nM for human amylin and 0.056 nM for human calcitonin (Fischer Munch et al., 2025). The Phase 1 paper describes potent agonism at the amylin receptors AMY1 and AMY3 and at the calcitonin receptor (Brændholt Olsen et al., 2026), and a 2026 review classes it as a dual amylin and calcitonin receptor agonist (Alhazmi & le Roux, 2026).
• Hindbrain satiety (area postrema, nucleus of the solitary tract) — The chemistry paper describes amylin as delaying gastric emptying and glucagon secretion and stimulating satiety signals, with the area postrema and nucleus of the solitary tract in the hindbrain proposed as the major site of its satiating effects (Fischer Munch et al., 2025). Where petrelintide itself acts in the human brain has not been published.
• Gastric emptying: not delayed in people — Native amylin, pramlintide and GLP-1 medicines have been shown to delay gastric emptying. In the two Phase 1 trials, petrelintide did not change it, measured by acetaminophen absorption in 24 participants given single doses of 0.7–2.4 mg or placebo, and at steady state in 48 participants given weekly doses up to 9.0 mg or placebo (Griffin et al., 2026, conference abstract).
• Albumin binding through a C20 fatty diacid (long action) — Petrelintide carries a C20 fatty diacid on its N-terminus through a γ-glutamic acid linker (Fischer Munch et al., 2025). The Phase 1 paper says it is “extensively but reversibly bound to albumin in the blood via a fatty acid moiety,” citing unpublished data. In people its half-life was about 10 days (mean 213–257 hours after single SubQ doses, 239 hours after IV), and bioavailability after a 0.35 mg SubQ dose was 77.4% (Brændholt Olsen et al., 2026).
• Stability by design (N-methylation, asparagine removal, lactam bridge) — Instead of pramlintide’s three prolines at positions 25, 28 and 29, petrelintide carries N-methyl groups on Gly24 and Ile26 against fibril formation. Asparagines prone to chemical degradation were deleted (positions 21 and 22) or replaced, and the disulfide bridge near the N-terminus was swapped for a lactam bridge, which the authors say removed disulfide shuffling and allowed formulation at neutral pH (Fischer Munch et al., 2025).
• Leptin (the company’s rationale) — Zealand’s announcements say amylin receptor activation “has been shown to reduce body weight by restoring sensitivity to the satiety hormone leptin.” One of the studies they cite gave amylin to obese rats, where it partially restored hypothalamic leptin signaling, and gave pramlintide with leptin to people, who lost 12.7% over 24 weeks (Roth et al., 2008). That study did not test petrelintide.

What the Research Shows

The results below are laboratory and rat studies. Every one comes from Zealand Pharma, some with Boehringer Ingelheim co-authors.

• One dose in lean rats — Petrelintide had a half-life of 33.8 hours in rats, and one injection was followed by a body-weight reduction of about 10% at 96 hours (Fischer Munch et al., 2025).
• Obese rats, 20 days — Diet-induced obese rats got 1, 3, 10 or 15 nmol/kg every other day. At 15 nmol/kg, cumulative food intake by day 20 was 298 g per rat versus 390 g on vehicle. The rats still gained weight, only less: +16.9% on vehicle, +8.7% at 3 nmol/kg, +3.8% at 10 nmol/kg and +4.4% at 15 nmol/kg (Fischer Munch et al., 2025).
• Fat and lean mass in obese rats — Over 30 days, body weight changed +3.3% on vehicle, −0.1% on liraglutide, and −4.1% and −7.8% on the two petrelintide regimens. On EchoMRI, petrelintide lowered fat mass against vehicle and showed “significant preservation of relative lean mass,” which liraglutide did not (Vestergaard et al., 2024, abstract 1662-P).
• High-fat food in obese rats — With both chow and a high-fat diet on offer, rats on petrelintide ate 646 g and 576 g of the high-fat diet over 30 days versus 834 g on vehicle and 796 g on liraglutide; chow intake did not change in any group (Vestergaard et al., 2024, abstract 1661-P).
• Eating pattern against semaglutide — In obese rats treated for three weeks, petrelintide, semaglutide and calorie restriction matched to them each cut body weight by 6.1–7.0%, against a 4.9% gain on vehicle. Only petrelintide significantly cut light-phase eating, and its sustained drop in intake came more from smaller meals than semaglutide’s did (Gradel et al., 2026, abstract).
• Mixed with semaglutide — In accelerated tests (four weeks at 40 °C), adding semaglutide to petrelintide in two formulations had no substantial effect on petrelintide’s rate of chemical breakdown or on aggregation (Fischer Munch et al., 2025). In obese rats, the two given together or mixed in one formulation lowered body weight and food intake more than vehicle or either drug alone (Eriksson et al., 2022, poster).

Human Data

All human data come from trials Zealand Pharma ran. Only the Phase 1 trials are in a peer-reviewed paper.

• Phase 1, single ascending dose (NCT05096598) — Randomized, double-blind and placebo-controlled at one center in Neuss, Germany: 64 healthy men, 48 of them on single doses of 0.04 to 2.4 mg SubQ or 0.35 mg IV. Absorption was slow (median time to peak 28–108 hours) and the half-life was about 10 days. Nausea and vomiting occurred only at the two highest SubQ doses, 1.4 and 2.4 mg (Brændholt Olsen et al., 2026).
• Phase 1, multiple ascending dose (NCT05613387) — Part 1: 20 men on 0.6 or 1.2 mg weekly, or placebo, for 6 weeks without a step-up. Part 2: 48 adults with a BMI of 27.0–39.9 (79% men, mean BMI 29.9) on weekly doses stepped up every 2 weeks to 2.4, 4.8 or 9.0 mg, or placebo, for 16 weeks. Mean body weight fell 4.8%, 8.6% and 8.3% in the three cohorts versus 1.7% on placebo (estimated differences −3.2, −7.0 and −6.7 points; p ≤ 0.0002), and waist circumference fell 5.0, 7.2 and 7.6 cm versus 1.9 cm. HbA1c, about 5.5% at baseline, did not change. Participants got no lifestyle program, and the highest-dose cohorts spent only 8 and 6 weeks on their target doses (Brændholt Olsen et al., 2026). In a post hoc look, women showed a consistently greater response than men across the three cohorts; the pooled placebo group held only 2 women (Hesse et al., 2025, abstract).
• Phase 2, ZUPREME-1 (NCT06662539) — Randomized 5:1, double-blind and placebo-controlled, at sites in the United States, Poland and Romania: 493 adults enrolled and 485 dosed (53% women; mean age 47, BMI 36.7, weight 107.1 kg), none with diabetes, on five doses or placebo alongside a reduced-calorie diet and more physical activity (Garvey et al., 2026, abstract; Zealand Pharma, March 5, 2026). The main goal, percent weight change at week 28, was met in all five dose groups, per the company; no week-28 numbers have been released. At week 42 (efficacy estimand), weight changed −8.7%, −9.2%, −10.7%, −10.5% and −10.2% across dose groups 1 to 5, versus −1.7% on placebo; the largest mean loss was in the third of the five groups (Zealand Pharma slides, March 5, 2026). The treatment-regimen estimand was “largely consistent,” with no numbers released. The company’s slides report roughly 6 percentage points more weight loss in women than in men, and about 3 points more in European than in US participants, at the maximally effective dose against placebo. At week 42, waist circumference fell 7.9–10.8 cm versus 4.3 cm, hsCRP 17–41% versus 6% and triglycerides 12–21% versus 9%, and Zealand said the full results would be published later in 2026 (Zealand Pharma, June 5, 2026).
• Phase 2, ZUPREME-2 (NCT06926842) — 221 adults with type 2 diabetes on metformin, with or without an SGLT2 inhibitor, randomized to three doses or placebo, with percent weight change at week 28 as the main result. It was completed on August 13, 2026. No results are posted; in August Zealand said topline results were expected in the second half of 2026 (Zealand Pharma, August 13, 2026).
• Pharmacokinetic studies — A study in people with impaired kidney function (39 enrolled) was completed in November 2025, and a study of four drug-product concentrations (48 enrolled) in March 2026; neither has posted results. A study in impaired liver function was recruiting on September 29, 2026 (NCT07076030, NCT07338214, NCT07682818).
• Phase 3 and the combination trial (registered, not started) — ZUPREME-3 (about 3,900 adults without type 2 diabetes), ZUPREME-4 (about 600 with type 2 diabetes) and ZUPREME-5 (about 2,500 aged 40 or older with established cardiovascular disease) each compare petrelintide with placebo on percent weight change at week 64. The Phase 2 ZYNERGY trial plans to enroll an estimated 486 adults to test petrelintide with enicepatide against each drug alone and placebo, with weight change at week 40 as its main result. All four were not yet recruiting on September 29, 2026 (NCT07843498, NCT07843485, NCT07843472, NCT07589686).

The evidence meter on the petrelintide card counts published human studies for the use on its tag, fat loss. The published studies are the two Phase 1 trials, so it reads “Human pilots.” ZUPREME-1’s results are company-reported and do not move it until they appear in a paper.

Reconstitution & Storage

No paper, trial record or company document read for this page describes petrelintide as a powder to reconstitute. The two trial records that name the form describe a “solution administered with a syringe” (NCT07076030, NCT07338214); ZUPREME-1 participants self-injected from a vial with a syringe (NCT06662539); and the Phase 3 trials use a “drug-device combination product” (NCT07843498). None of them gives a vial strength, a storage temperature, a shelf life or an in-use period for the trial product, so there is no mixing table here. The one research-chemical listing found for this page sells petrelintide as a solid, labelled “For research only, Do not use for Human!” (PubChem, CID 172915807).

The chemistry paper’s stability data are laboratory stress tests, not storage instructions. At 1–10 mg/mL and pH 6.1–7.4, formulations showed no fibrillation over up to a month at 40 °C, and after one week at 40 °C, 0.2% or less covalent oligomers and 3% or less chemical degradation (Fischer Munch et al., 2025).

• Route in the documents — Under the skin, once a week. In the Phase 1 trials, every injection went into a lifted skin fold of the abdominal wall; single injections were up to 0.7 mL in the single-dose trial and up to 0.3 mL in part 1 of the multiple-dose trial, and in part 2 up to 1.0 mL, with the highest doses split into up to three injections (Brændholt Olsen et al., 2026).
• Storage — No storage instructions for the trial product appear in the documents read for this page.

→ Peptide Calculator — vial-to-syringe math

Side Effects & Risks

What the trials recorded, with numbers as published:

• Nausea — The most common gastrointestinal side effect in ZUPREME-1: 19.6% on petrelintide versus 6.2% on placebo, and more than 75% of gastrointestinal adverse events were mild (Garvey et al., 2026, abstract). The company adds that 80% of nausea events were mild, one was severe (in the highest-dose group), and almost none occurred after participants reached their target dose (Zealand Pharma slides, March 5, 2026). In the 16-week Phase 1 trial, 16.7–33.3% of participants on petrelintide reported nausea versus 16.7% on placebo (Brændholt Olsen et al., 2026).
• Vomiting, diarrhea and constipation — In ZUPREME-1, vomiting was 3.0% on petrelintide versus 6.2% on placebo, and diarrhea and constipation were under 7.5% in both groups (Garvey et al., 2026, abstract); the company reports no vomiting at the maximally effective dose (Zealand Pharma, March 5, 2026). In the 16-week Phase 1 trial, the one participant who vomited stopped treatment after the third dose because of moderate nausea and vomiting (Brændholt Olsen et al., 2026).
• Fast exposure — Nausea followed single doses of 1.4 and 2.4 mg in 67% and 83% of participants, and vomiting followed 2.4 mg in 67%, against nausea in 14% and 29% on weekly 0.6 and 1.2 mg, which reach similar blood levels at steady state (Griffin et al., 2024, abstract). ZUPREME-1 stepped doses up every four weeks; the company says nausea was less common than in the Phase 1 trial, which stepped up every two weeks (Zealand Pharma, March 5, 2026).
• Stopping treatment — In ZUPREME-1, 4.5% of participants on petrelintide stopped treatment because of adverse events, 4.8% at the maximally effective dose, versus 4.9% on placebo; 1.5% stopped because of gastrointestinal adverse events, versus none on placebo (Zealand Pharma slides, March 5, 2026). Withdrawal from the trial for any reason was 8.4% on petrelintide and 13.6% on placebo (Zealand Pharma, March 5, 2026).
• Appetite — Decreased appetite was reported by 58.3–83.3% of participants on petrelintide versus 41.7% on placebo in the 16-week Phase 1 trial, which the authors call consistent with how amylin agonists work (Brændholt Olsen et al., 2026).
• Heart rate — In the multiple-dose trial, mean pulse rate fell after dosing and was about 5 beats per minute below baseline toward the end of treatment (Brændholt Olsen et al., 2026).
• Injection sites — In Phase 1, all injection-site reactions were mild and transient, mostly in cohorts that got up to three injections per dose (Brændholt Olsen et al., 2026). In ZUPREME-1 the company calls the rate “very low and consistent with placebo” (Zealand Pharma, March 5, 2026).
• Serious events and antibodies — The Phase 1 trials reported no serious or severe adverse events, no events of special interest (suspected liver injury, pancreatic or biliary disease) and no participant with anti-drug antibodies (Brændholt Olsen et al., 2026). For ZUPREME-1 the company reports “no unexpected safety signals,” including for alopecia, fatigue and neuropsychiatric events such as headache and depression (Zealand Pharma, March 5, 2026).
• Pregnancy — No pregnancy data have been published. The single-dose trial enrolled only men, the multiple-dose trial only men and women who could not become pregnant, and ZUPREME-1 required women who could become pregnant to use highly effective contraception during the trial and for 10 weeks after the last injection (Brændholt Olsen et al., 2026; NCT05096598, NCT05613387, NCT06662539).
• Kidney and liver — Kidney-impairment results have not been posted, and the liver-impairment study is still recruiting (NCT07076030, NCT07682818).
• Drug interactions — No interaction study of petrelintide has been published.
• WADA — Petrelintide is not named on the 2026 Prohibited List. Section S0 prohibits at all times substances not addressed elsewhere on the List “with no current approval by any governmental regulatory health authority for human therapeutic use (e.g. drugs under pre-clinical or clinical development or discontinued…)” (World Anti-Doping Agency, 2026).

Bloodwork & Monitoring

No monitoring guidance for petrelintide has been published, and there is no label. These are what the trials measured:

• Body weight and waist circumference — Body weight is the main result of every efficacy trial, and waist circumference a secondary one (Brændholt Olsen et al., 2026; NCT06662539; NCT06926842).
• HbA1c and fasting glucose — Secondary endpoints in ZUPREME-1 and ZUPREME-2; in the 16-week Phase 1 trial, HbA1c stayed at about 5.5% (Brændholt Olsen et al., 2026; NCT06662539; NCT06926842).
• hsCRP and fasting lipids — Secondary endpoints in ZUPREME-1, where the company reports hsCRP falling 17–41% and triglycerides 12–21% on petrelintide (Zealand Pharma, June 5, 2026).
• Pulse and blood pressure — Vital signs in Phase 1, where pulse fell about 5 beats per minute; blood pressure was among the cardiovascular risk factors in ZUPREME-1 (Brændholt Olsen et al., 2026; Garvey et al., 2026, abstract).
• Liver, pancreas and gallbladder — Suspected liver injury, pancreatic disease and biliary disease were tracked as adverse events of special interest in Phase 1; none was reported (Brændholt Olsen et al., 2026).
• Low blood sugar — ZUPREME-2 counts severe or clinically significant hypoglycemic episodes in its participants with type 2 diabetes (NCT06926842).
• Anti-drug antibodies — Measured in Phase 1 (none found) and through week 51 in ZUPREME-1 (Brændholt Olsen et al., 2026; NCT06662539).
• Which tests fit a given person — A question for a licensed healthcare provider. This page can’t answer it.

Commonly Stacked With

No study in people has tested petrelintide with another drug yet. The documents show one combination planned for people and one tested in the laboratory and in rats, recorded as documented.

→ Peptide Calculator — vial-to-syringe math

Legal Status

Related Compounds

People researching petrelintide often also look at these:

Next Steps

References

1. Fischer Munch H, Just R, Mosolff Mathiesen J, Eriksson PO, Skodborg Villadsen J, Vestergaard B, et al. Development of Petrelintide: a Potent, Stable, Long-Acting Human Amylin Analogue. J Med Chem. 2025;68(22):23925-23940. PMID: 41217931. DOI: 10.1021/acs.jmedchem.5c01185. (Design, receptor potency, rat data, co-formulation with semaglutide; Zealand Pharma and Boehringer Ingelheim authors.)
2. Brændholt Olsen M, Griffin J, Hövelmann U, Macura S, Fredsted Hagen B, Hesse D, Heise T. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Petrelintide for Weight Management: Two Randomized, Controlled Phase 1 Trials. Diabetes Obes Metab. 2026;28(7):5915-5925. PMID: 42017294. DOI: 10.1111/dom.70753. (Funded by Zealand Pharma; four authors are Zealand employees and one a former employee.)
3. Griffin J, Hövelmann U, Melgaard AE, Macura S, Hammer M, Johansen T, Olsen MB. 1668-P: Novel Once-Weekly Amylin Analog Petrelintide (ZP8396) Is Well Tolerated with Improved GI Tolerability after Multiple Dosing. Diabetes. 2024;73(Supplement_1):1668-P. DOI: 10.2337/db24-1668-p. (Conference abstract.)
4. Vestergaard B, Baader-Pagler T, Griffin J. 1661-P: Petrelintide (ZP8396) Selectively Reduces Intake of High-Fat Diet in DIO Rats. Diabetes. 2024;73(Supplement_1):1661-P. DOI: 10.2337/db24-1661-p. (Conference abstract.)
5. Vestergaard B, Baader-Pagler T, Griffin J. 1662-P: Petrelintide (ZP8396) Significantly Reduces Fat Mass while Preserving Lean Mass in DIO Rats. Diabetes. 2024;73(Supplement_1):1662-P. DOI: 10.2337/db24-1662-p. (Conference abstract.)
6. Hesse D, Olsen MB, Griffin J, Hövelmann U, Macura S, Johansen T, et al. 1773-P: Effects of the Novel Long-Acting Amylin Analogue Petrelintide on Body Weight and Waist Circumference by Sex in a Phase 1 Trial. Diabetes. 2025;74(Supplement_1):1773-P. DOI: 10.2337/db25-1773-p. (Conference abstract.)
7. Griffin J, Olsen MB, Andersen IH, Larsen L, Hesse D, Hövelmann U, Heise T. 2598-P: Long-Acting Amylin Analog Petrelintide Does Not Delay Gastric Emptying. Diabetes. 2026;75(Supplement_1):2598-P. DOI: 10.2337/db26-2598-p. (Conference abstract.)
8. Gradel AKJ, Vestergaard B, Griffin J, Torz Pedersen L. 2548-P: Petrelintide Elicits Distinct Effects on Eating Pattern and Maintains Locomotor Activity Compared with Semaglutide in Rats with Diet-Induced Obesity. Diabetes. 2026;75(Supplement_1):2548-P. DOI: 10.2337/db26-2548-p. (Conference abstract.)
9. Garvey WT, Connery L, Dinesen M, Hagen BF, Larsen L, Hesse D. 3083-LB: Petrelintide, a Human Amylin Analog for the Treatment of Obesity: Efficacy and Safety from the Phase 2 Trial, ZUPREME 1. Diabetes. 2026;75(Supplement_1):3083-LB. DOI: 10.2337/db26-3083-lb. (Late-breaking conference abstract, ADA 2026; ZUPREME-1 has no full paper yet.)
10. Eriksson PO, Lundqvist J, Griffin J, Wenander C, Flachs Nielsen A, Toft Mossing J, Skarbaliene J, Kendall DM. Amylin analog ZP8396 can be co-formulated with semaglutide to provide additive anti-obesity effect in the DIO rat model. Poster, ObesityWeek, November 1–4, 2022, San Diego. zealandpharma.com/media/0gnfxg4b/zp8396-sema-coformulation-obesityweek-2022.pdf. Read September 29, 2026.
11. Roth JD, Roland BL, Cole RL, Trevaskis JL, Weyer C, Koda JE, et al. Leptin responsiveness restored by amylin agonism in diet-induced obesity: evidence from nonclinical and clinical studies. Proc Natl Acad Sci U S A. 2008;105(20):7257-7262. PMID: 18458326. (Amylin in rats, and pramlintide with leptin in people; not petrelintide.)
12. Alhazmi A, le Roux CW. Amylin Analogs: The Next Major Class of Weight Loss Therapy: A Review of Experimental Data and Early-Phase Clinical Trials. Diabetes Obes Metab. 2026;28(Suppl 5):42-50. PMID: 42452898. DOI: 10.1111/dom.71074. (Commissioned for a themed issue funded by Zealand Pharma, per the article; the second author declares advisory roles with Roche and Zealand Pharma.)
13. Roche. Roche enters into an exclusive collaboration & licensing agreement with Zealand Pharma to co-develop and co-commercialise petrelintide as a potential foundational therapy for people with overweight and obesity. Media release, March 12, 2025. roche.com/media/releases/med-cor-2025-03-12. Read September 29, 2026.
14. Zealand Pharma. Company announcement No. 3/2026: Zealand Pharma announces positive Phase 2 results for petrelintide, an amylin analog with potential to redefine the weight management experience for people living with overweight and obesity. March 5, 2026. globenewswire.com/news-release/2026/03/05/3250569/0/en/Zealand-Pharma-announces-positive-Phase-2-results-for-petrelintide-an-amylin-analog-with-potential-to-redefine-the-weight-management-experience-for-people-living-with-overweight-and-obesity.html. Read September 29, 2026.
15. Zealand Pharma. Petrelintide topline data, Phase 2 ZUPREME-1 trial. Conference-call presentation, March 5, 2026. zealandpharma.com/media/ouvbokrh/20260305_zupreme-1-conference-call-presentation.pdf. Read September 29, 2026. (Week-42 results by dose group; tolerability and discontinuation charts.)
16. Roche. Roche announces positive Phase II results for petrelintide, an amylin analog developed for people living with overweight and obesity. Investor update, March 5, 2026. roche.com/investors/updates/inv-update-2026-03-05. Read September 29, 2026.
17. Zealand Pharma. Company announcement No. 11/2026: Zealand Pharma and Roche to advance petrelintide, an amylin analog, to Phase 3 trials for chronic weight management. April 29, 2026. Read at inderes.fi/en/releases/zealand-pharma-and-roche-to-advance-petrelintide-an-amylin-analog-to-phase-3-trials-for-chronic-weight-management, September 29, 2026.
18. Zealand Pharma. New data from Phase 2 ZUPREME-1 trial at the American Diabetes Association 2026 Scientific Sessions further support potential of petrelintide to redefine the weight management experience for people living with overweight and obesity. Press release, June 5, 2026. Read at biospace.com/press-releases/new-data-from-phase-2-zupreme-1-trial-at-the-american-diabetes-association-2026-scientific-sessions-further-support-potential-of-petrelintide-to-redefine-the-weight-management-experience-for-people-living-with-overweight-and-obesity, September 29, 2026.
19. Zealand Pharma. Company announcement No. 39/2026: Zealand Pharma Announces Financial Results for the First Half of 2026. August 13, 2026. Read at inderes.dk/en/releases/zealand-pharma-announces-financial-results-for-the-first-half-of-2026, September 29, 2026.
20. ClinicalTrials.gov. NCT05096598 (single ascending dose, completed January 2023) and NCT05613387 (multiple ascending dose, completed June 2024), Zealand Pharma. Read September 29, 2026. EU Clinical Trials Register: EudraCT 2021-001712-28 and 2022-001744-26, as given in the Phase 1 paper.
21. ClinicalTrials.gov. NCT06662539, ZUPREME-1: once-weekly petrelintide versus placebo for obesity or overweight with comorbidities (Phase 2, Zealand Pharma; completed March 2026). Read September 29, 2026.
22. ClinicalTrials.gov. NCT06926842, ZUPREME-2: once-weekly petrelintide versus placebo in overweight or obesity and type 2 diabetes (Phase 2, Zealand Pharma; completed August 13, 2026; no results posted). Read September 29, 2026.
23. ClinicalTrials.gov. NCT07843498 (ZUPREME-3), NCT07843485 (ZUPREME-4) and NCT07843472 (ZUPREME-5): Phase 3, Hoffmann-La Roche with Zealand Pharma; first posted September 28, 2026; not yet recruiting. Read September 29, 2026.
24. ClinicalTrials.gov. NCT07589686, ZYNERGY: petrelintide co-administered with enicepatide (RO7795068, CT-388), Phase 2, Hoffmann-La Roche with Zealand Pharma; not yet recruiting. Read September 29, 2026.
25. ClinicalTrials.gov. NCT07076030 (impaired kidney function, completed), NCT07338214 (four drug-product concentrations, completed) and NCT07682818 (impaired liver function, recruiting), Zealand Pharma. Read September 29, 2026.
26. PubChem. Petrelintide (ZP8396), CID 172915807: molecular formula C185H305N49O61, molecular weight 4192 g/mol; its Chemical Vendors section lists one supplier, whose product page (excenen.com/petrelintide.html, read September 29, 2026) sells it as a solid labelled “For research only, Do not use for Human!”. pubchem.ncbi.nlm.nih.gov/compound/172915807. Read September 29, 2026.
27. World Anti-Doping Agency. Prohibited List 2026 (in effect January 1, 2026). S0, Non-approved substances. wada-ama.org.
28. FDA. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act (categories 1–3). Updated May 14, 2026. fda.gov/media/94155/download. And 21 CFR 216.23, bulk drug substances that can be used in compounding under section 503A (ecfr.gov, version of September 25, 2026).
29. FDA. Drugs@FDA, NDC directory and drug labels (openFDA, api.fda.gov), and NLM DailyMed (dailymed.nlm.nih.gov): searches for “petrelintide,” September 29, 2026 (no records).

Related Research

• CagrilintideLong-Acting Amylin Analog
• CagriSemaCagrilintide + Semaglutide
• EloralintideSelective Amylin Receptor Agonist
• AmycretinGLP-1, Amylin and Calcitonin Receptor Agonist in One Molecule
• PramlintideShort-Acting Amylin Analog (Symlin)
• SemaglutideGLP-1 Receptor Agonist; mixed with petrelintide in lab and rat studies